Aripiprazole Tablet
Product Images NDC 46708-254

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 46708-254). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg 30's Hdpe Bottle Pack (Aripiprazole 10mg)

Aripiprazole 10 mg tablets label showing a package of 30 oral tablets. Produced by Alembic Pharmaceuticals Limited, the label includes storage instructions, a barcode, and information that each tablet contains 10 mg of aripiprazole USP. The label also notes the product is prescription only with directions to dispense with a medication guide.*

FDA Label Image

15 mg 30's Hdpe Bottle Pack (Aripiprazole 15mg)

The image shows a packaging label for Aripiprazole Tablets 15 mg by Alembic Pharmaceuticals Limited. The label includes dosage strength (15 mg), quantity (30 tablets), and storage instructions. It also displays an NDC number (46708-257-30), barcode, manufacturer information in Gujarat, India, and a reminder to dispense with medication guide.*

FDA Label Image

20 mg 30's Hdpe Bottle Pack (Aripiprazole 20mg)

Label for Aripiprazole Tablets 20 mg, oral tablets manufactured by Alembic Pharmaceuticals Limited. The label indicates a package size of 30 tablets and includes storage instructions at 20° to 25°C with permitted excursions. The NDC number 46708-258-30 and barcode are visible, along with directions for pharmacist dispensing and mention of controlled room temperature guidelines.*

FDA Label Image

2 mg 30's Hdpe Bottle Pack (Aripiprazole 2mg)

Aripiprazole 2 mg tablets label by Alembic Pharmaceuticals Limited. The label includes NDC 46708-254-30 and indicates the product contains 30 tablets for oral use. Storage instructions specify 20° to 25°C with allowed excursions. It includes barcode and manufacturing details from Gujarat, India.*

FDA Label Image

30 mg 30's Hdpe Bottle Pack (Aripiprazole 30mg)

Aripiprazole Tablets 30 mg label showing NDC 46708-259-30. The label indicates each tablet contains 30 mg aripiprazole USP, with a package count of 30 tablets. It includes storage instructions, manufacturer information for Alembic Pharmaceuticals Limited, and states the product is Rx only. The label also features a barcode and batch/expiry placeholders.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A forest plot chart showing fold change and 90% confidence intervals for various drugs' pharmacokinetic parameters (AU C, C max, D W/DRP) relative to a reference without interacting drugs. The y-axis lists drug names and cytochrome enzymes, and the x-axis shows change relative to reference from 0.3 to 3. The chart visually compares the effects of interacting drugs on pharmacokinetics.*

FDA Label Image

5 mg 30's Hdpe Bottle Pack (Aripiprazole 5mg)

Label for Aripiprazole tablets 5 mg by Alembic Pharmaceuticals Limited. The label shows 30 tablets in the package with a storage recommendation of 20° to 25°C (68° to 77°F), allowing excursions to 15°-30°C (59°-86°F). It includes the NDC 46708-255-30 and notes it is Rx only. The label also instructs pharmacists to dispense with a medication guide and provides manufacturing details and batch/expiry placeholders.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic chart titled "Effect of Other Drugs on Aripiprazole" showing fold change and 90% confidence intervals for AUC and Cmax of Dehydro-Aripiprazole. It compares the impact of various drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others like valproate, lithium, and lorazepam, on Aripiprazole exposure relative to a reference without interacting drugs.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing changes relative to reference for various special populations, including CYP2D6 enzyme metabolizers, gender, age groups, hepatic impairment levels, and severe renal impairment. The graph plots fold changes in AUC and Cmax with confidence intervals for each category.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic chart showing fold changes and 90% confidence intervals of Dehydro-Aripiprazole levels related to various factors including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment. The x-axis represents change relative to reference, while the y-axis compares AUC and Cmax parameters for each factor.*

FDA Label Image

Figure 6 (Aripiprazole Figure6)

A Kaplan-Meier curve depicting the proportion of subjects with relapse over days from randomization, comparing Aripiprazole (solid line) and placebo (dashed line). The x-axis shows days from randomization up to 182 days, while the y-axis shows the proportion of relapse from 0.0 to 1.0. The number of subjects at risk is listed below the x-axis for both Aripiprazole and placebo groups at various time points.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of Aripiprazole showing its molecular arrangement with key aromatic and heterocyclic rings, including chlorinated phenyl and piperazine moieties linked through an alkyl chain to a quinolinone ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.